This document is an excerpt from the EUR-Lex website
Document 62024TA0645
Case T-645/24: Judgment of the General Court of 19 November 2025 – +pharma arzneimittel v EUIPO – PlusQuam Pharma (PlusQuam +PHARMA) (EU trade mark – Opposition proceedings – Application for EU figurative mark PlusQuam +PHARMA – Earlier national word mark +PHARMA – Relative grounds for refusal – Article 8(1)(b) and (5) of Regulation 2017/1001 – Enhanced distinctiveness of the earlier mark through use – Reputation – Proof of use)
Case T-645/24: Judgment of the General Court of 19 November 2025 – +pharma arzneimittel v EUIPO – PlusQuam Pharma (PlusQuam +PHARMA) (EU trade mark – Opposition proceedings – Application for EU figurative mark PlusQuam +PHARMA – Earlier national word mark +PHARMA – Relative grounds for refusal – Article 8(1)(b) and (5) of Regulation 2017/1001 – Enhanced distinctiveness of the earlier mark through use – Reputation – Proof of use)
Case T-645/24: Judgment of the General Court of 19 November 2025 – +pharma arzneimittel v EUIPO – PlusQuam Pharma (PlusQuam +PHARMA) (EU trade mark – Opposition proceedings – Application for EU figurative mark PlusQuam +PHARMA – Earlier national word mark +PHARMA – Relative grounds for refusal – Article 8(1)(b) and (5) of Regulation 2017/1001 – Enhanced distinctiveness of the earlier mark through use – Reputation – Proof of use)
OJ C, C/2026/330, 26.1.2026, ELI: http://data.europa.eu/eli/C/2026/330/oj (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
Official Journal |
EN C series |
|
C/2026/330 |
26.1.2026 |
Judgment of the General Court of 19 November 2025 – +pharma arzneimittel v EUIPO – PlusQuam Pharma (PlusQuam +PHARMA)
(Case T-645/24) (1)
(EU trade mark - Opposition proceedings - Application for EU figurative mark PlusQuam +PHARMA - Earlier national word mark +PHARMA - Relative grounds for refusal - Article 8(1)(b) and (5) of Regulation 2017/1001 - Enhanced distinctiveness of the earlier mark through use - Reputation - Proof of use)
(C/2026/330)
Language of the case: German
Parties
Applicant: +pharma arzneimittel GmbH (Graz, Austria) (represented by: L. Wiltschek and D. Plasser, lawyers)
Defendant: European Union Intellectual Property Office (represented by: M. Eberl, acting as Agent)
Other party to the proceedings before the Board of Appeal of EUIPO: PlusQuam Pharma, SL (Badajoz, Spain)
Re:
By its action under Article 263 TFEU, the applicant seeks the annulment and alteration of the decision of the Second Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 7 November 2024 (Case R 1217/2024-2).
Operative part of the judgment
The Court:
|
1. |
Annuls the decision of the Second Board of Appeal of the European Union Intellectual Property Office (EUIPO) of 7 November 2024 (Case R 1217/2024-2); |
|
2. |
Dismisses the action as to the remainder; |
|
3. |
Orders EUIPO to bear its own costs and to pay those incurred by +pharma arzneimittel GmbH. |
ELI: http://data.europa.eu/eli/C/2026/330/oj
ISSN 1977-091X (electronic edition)